OVERSEA CHINESE BANKING Corp Ltd Increases Stock Holdings in Insulet Co. (NASDAQ:PODD)

OVERSEA CHINESE BANKING Corp Ltd boosted its stake in shares of Insulet Co. (NASDAQ:PODD) by 4.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,076 shares of the medical instruments supplier’s stock after buying an additional 48 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Insulet were worth $250,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Blue Trust Inc. raised its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC bought a new stake in Insulet in the second quarter worth about $32,000. Venturi Wealth Management LLC boosted its position in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. lifted its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares during the last quarter. Finally, CVA Family Office LLC boosted its holdings in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the period.

Insulet Price Performance

PODD opened at $269.06 on Thursday. The firm has a market capitalization of $18.87 billion, a PE ratio of 46.07, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. The business’s 50-day moving average is $235.96 and its two-hundred day moving average is $206.47. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.40. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PODD. UBS Group boosted their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Canaccord Genuity Group upped their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Citigroup raised their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Barclays increased their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Morgan Stanley lifted their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.